Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu peptide vaccine|BIOLOGICAL: sargramostim|DRUG: rintatolimod
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)